While foreign investors have been reducing their exposure to Indian pharma, some leading domestic institutional investors ...
After a year of dwindling coffers and repeated layoff rounds, the Southern California biotech firm Viracta Therapeutics has ...
Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences ...
Ideaya is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028. Click ...
Financial writer advises caution on Jyong Biotech Ltd. IPO due to high debt, legal issues, and FDA challenges. Click for my ...
Learn more about whether Legend Biotech Corporation or Protagonist Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Stratos Wealth Partners LTD. trimmed its position in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 17.9% ...
Learn more about whether Halozyme Therapeutics, Inc. or Twist Bioscience Corporation is a better investment based on AAII's ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Prothena (NASDAQ:PRTA – Free Report) had its price target boosted by Oppenheimer from $58.00 to $62.00 in a report published on Friday,Benzinga reports. They currently have an outperform rating on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results